Inhibrx Stock Price To Book

INBX Stock

USD 14.02 0.04 0.29%

Inhibrx fundamentals help investors to digest information that contributes to Inhibrx's financial success or failures. It also enables traders to predict the movement of Inhibrx Stock. The fundamental analysis module provides a way to measure Inhibrx's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inhibrx stock.

Total Current Liabilities Other Current Liab

Price To Book Ratio is likely to rise to 43.23 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Inhibrx Company Price To Book Analysis

Inhibrx's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Current Inhibrx Price To Book

1.13 X

Most of Inhibrx's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inhibrx is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Inhibrx Price To Book Driver Correlations

Understanding the fundamental principles of building solid financial models for Inhibrx is extremely important. It helps to project a fair market value of Inhibrx Stock properly, considering its historical fundamentals such as Price To Book. Since Inhibrx's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inhibrx's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inhibrx's interrelated accounts and indicators.

	Net Tangible Assets	Retained Earnings	Accounts Payable	Total Current Assets	Property Plant Equipment	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Long Term Debt	Net Receivables	Total Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Deferred Long Term Liab	Capital Stock	Common Stock	Long Term Debt Total	Capital Surpluse
Net Tangible Assets		-0.72	0.65	0.81	0.14	0.81	0.98	-0.71	-0.94	0.68	-0.02	0.5	0.84	-0.59	0.82	-0.78	-0.49	0.91	0.91	0.67	0.63
Retained Earnings	-0.72		-0.63	-0.97	-0.17	-0.97	-0.7	0.57	0.76	-0.97	0.26	-0.87	-0.94	0.75	-0.96	0.59	0.81	-0.83	-0.83	-0.97	-0.9
Accounts Payable	0.65	-0.63		0.69	0.68	0.71	0.76	-0.3	-0.85	0.56	-0.2	0.6	0.66	-0.72	0.68	-0.82	-0.3	0.71	0.71	0.5	0.52
Total Current Assets	0.81	-0.97	0.69		0.18	1.0	0.81	-0.62	-0.85	0.97	-0.36	0.86	0.99	-0.76	1.0	-0.71	-0.72	0.86	0.86	0.96	0.9
Property Plant Equipment	0.14	-0.17	0.68	0.18		0.21	0.28	0.46	-0.38	0.07	-0.12	0.21	0.1	-0.68	0.17	-0.63	0.06	0.11	0.11	-0.03	0.0
Total Assets	0.81	-0.97	0.71	1.0	0.21		0.81	-0.6	-0.86	0.97	-0.36	0.87	0.99	-0.78	1.0	-0.73	-0.72	0.85	0.85	0.95	0.89
Total Stockholder Equity	0.98	-0.7	0.76	0.81	0.28	0.81		-0.65	-0.98	0.67	-0.08	0.53	0.83	-0.65	0.82	-0.87	-0.41	0.9	0.9	0.63	0.62
Current Deferred Revenue	-0.71	0.57	-0.3	-0.62	0.46	-0.6	-0.65		0.59	-0.59	-0.08	-0.39	-0.67	0.04	-0.64	0.27	0.47	-0.76	-0.76	-0.64	-0.61
Net Debt	-0.94	0.76	-0.85	-0.85	-0.38	-0.86	-0.98	0.59		-0.72	0.16	-0.62	-0.87	0.73	-0.86	0.89	0.45	-0.91	-0.91	-0.68	-0.67
Long Term Debt	0.68	-0.97	0.56	0.97	0.07	0.97	0.67	-0.59	-0.72		-0.43	0.9	0.96	-0.71	0.97	-0.59	-0.75	0.76	0.76	0.99	0.93
Net Receivables	-0.02	0.26	-0.2	-0.36	-0.12	-0.36	-0.08	-0.08	0.16	-0.43		-0.42	-0.38	0.33	-0.38	0.31	0.15	0.08	0.08	-0.38	-0.28
Total Liab	0.5	-0.87	0.6	0.86	0.21	0.87	0.53	-0.39	-0.62	0.9	-0.42		0.83	-0.77	0.86	-0.51	-0.49	0.69	0.69	0.87	0.95
Net Invested Capital	0.84	-0.94	0.66	0.99	0.1	0.99	0.83	-0.67	-0.87	0.96	-0.38	0.83		-0.72	0.99	-0.7	-0.69	0.87	0.87	0.95	0.89
Short Long Term Debt	-0.59	0.75	-0.72	-0.76	-0.68	-0.78	-0.65	0.04	0.73	-0.71	0.33	-0.77	-0.72		-0.76	0.81	0.39	-0.6	-0.6	-0.63	-0.67
Net Working Capital	0.82	-0.96	0.68	1.0	0.17	1.0	0.82	-0.64	-0.86	0.97	-0.38	0.86	0.99	-0.76		-0.73	-0.69	0.86	0.86	0.95	0.9
Short Term Debt	-0.78	0.59	-0.82	-0.71	-0.63	-0.73	-0.87	0.27	0.89	-0.59	0.31	-0.51	-0.7	0.81	-0.73		0.25	-0.65	-0.65	-0.5	-0.47
Deferred Long Term Liab	-0.49	0.81	-0.3	-0.72	0.06	-0.72	-0.41	0.47	0.45	-0.75	0.15	-0.49	-0.69	0.39	-0.69	0.25		-0.54	-0.54	-0.79	-0.56
Capital Stock	0.91	-0.83	0.71	0.86	0.11	0.85	0.9	-0.76	-0.91	0.76	0.08	0.69	0.87	-0.6	0.86	-0.65	-0.54		1.0	0.76	0.81
Common Stock	0.91	-0.83	0.71	0.86	0.11	0.85	0.9	-0.76	-0.91	0.76	0.08	0.69	0.87	-0.6	0.86	-0.65	-0.54	1.0		0.76	0.81
Long Term Debt Total	0.67	-0.97	0.5	0.96	-0.03	0.95	0.63	-0.64	-0.68	0.99	-0.38	0.87	0.95	-0.63	0.95	-0.5	-0.79	0.76	0.76		0.93
Capital Surpluse	0.63	-0.9	0.52	0.9	0.0	0.89	0.62	-0.61	-0.67	0.93	-0.28	0.95	0.89	-0.67	0.9	-0.47	-0.56	0.81	0.81	0.93

Click cells to compare fundamentals

Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Competition

Predict Inhibrx

Price Book Value Ratio Over Time

Inhibrx Book Value Per Share

Book Value Per Share

0.97

At this time, Inhibrx's Book Value Per Share is fairly stable compared to the past year.

Based on the latest financial disclosure, Inhibrx has a Price To Book of 1.134 times. This is 95.58% lower than that of the Biotechnology sector and 81.23% lower than that of the Health Care industry. The price to book for all United States stocks is 88.08% higher than that of the company.

Inhibrx Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inhibrx's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inhibrx could also be used in its relative valuation, which is a method of valuing Inhibrx by comparing valuation metrics of similar companies.

Inhibrx is currently under evaluation in price to book category among its peers.

Inhibrx ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inhibrx's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inhibrx's managers, analysts, and investors.

Environmental

Governance

Social

Inhibrx Fundamentals

	Return On Equity	-20.31
	Return On Asset	-0.57
	Profit Margin	1,020 %
	Current Valuation	7.88 M
	Shares Outstanding	14.48 M
	Shares Owned By Insiders	23.54 %
	Shares Owned By Institutions	67.49 %
	Number Of Shares Shorted	976.67 K
	Price To Book	1.13 X
	Price To Sales	119.96 X
	Revenue	1.8 M
	Gross Profit	(107.99 M)
	EBITDA	(206.69 M)
	Net Income	(241.36 M)
	Cash And Equivalents	176.38 M
	Cash Per Share	4.52 X
	Total Debt	210.14 M
	Debt To Equity	4.22 %
	Current Ratio	7.51 X
	Book Value Per Share	15.15 X
	Cash Flow From Operations	(193.31 M)
	Short Ratio	14.06 X
	Earnings Per Share	119.39 X
	Target Price	15.0
	Number Of Employees	166
	Beta	2.88
	Market Capitalization	202.37 M
	Total Asset	307.89 M
	Retained Earnings	(613.73 M)
	Working Capital	239.05 M
	Net Asset	307.89 M

About Inhibrx Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Inhibrx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibrx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibrx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC